Literature DB >> 24022385

Streptococcus bovis bacteraemia: an evaluation of the long-term effect on cardiac outcomes.

Gerard J Fitzmaurice1, Adrian J McKenna, Jamie Murphy, Ronan McMullan, Mark E O'Donnell.   

Abstract

INTRODUCTION: Streptococcus bovis can lead to bacteraemia, septicaemia, and ultimately endocarditis. The objective of this study was to evaluate the long-term implications of S. bovis endocarditis on cardiac morbidity and mortality.
METHODS: A retrospective cohort study was performed between January 2000 and March 2009 to assess all patients diagnosed with S. bovis bacteraemia from the Belfast Health and Social Care Trust. The primary end-point for cardiac investigations was the presence of endocarditis. Secondary end-points included referral for cardiac surgery and overall mortality.
RESULTS: Sixty-one positive S. bovis blood cultures from 43 patients were included. Following echocardiography, seven patients were diagnosed with infective endocarditis (16.3 % of total patients); four patients (9.3 %) had native valve involvement while three (7.0 %) had prosthetic valve infection. Five of these seven patients had more than one positive S. bovis culture (71.4 %). Three had significant valve dysfunction that warranted surgical repair/replacement, one of whom was unfit for surgery. There was a 100 % recurrence rate amongst the valve replacement patients (n = 2) and six patients with endocarditis had colorectal pathology. Patients with endocarditis had similar long-term survival as those with non-endocarditic bacteraemia (57.1 % alive vs. 50 % of non-endocarditis patients, p = 0.73).
CONCLUSION: Streptococcus bovis endocarditis patients tended to have pre-existing valvular heart disease and those with prosthetic heart valves had higher surgical intervention and relapse rates. These patients experienced a higher rate of co-existing colorectal pathology but currently have reasonable long-term outcomes. This may suggest that they represent a patient population that merits consideration for an early surgical strategy to maximise long-term results, however, further evaluation is warranted.

Entities:  

Mesh:

Year:  2013        PMID: 24022385     DOI: 10.1007/s11748-013-0316-3

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  18 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Septic arthritis due to Streptococcus bovis as presenting sign of 'silent' colon carcinoma.

Authors:  C García-Porrúa; M A González-Gay; J R Monterroso; A Sánchez-Andrade; A González-Ramirez
Journal:  Rheumatology (Oxford)       Date:  2000-03       Impact factor: 7.580

3.  Bacteriological Studies in Endocarditis.

Authors:  W J Macneal; A Blevins
Journal:  J Bacteriol       Date:  1945-06       Impact factor: 3.490

4.  Carriage of group D streptococci in the human bowel.

Authors:  C J Noble
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

5.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

6.  Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer.

Authors:  Gilbert Habib; Bruno Hoen; Pilar Tornos; Franck Thuny; Bernard Prendergast; Isidre Vilacosta; Philippe Moreillon; Manuel de Jesus Antunes; Ulf Thilen; John Lekakis; Maria Lengyel; Ludwig Müller; Christoph K Naber; Petros Nihoyannopoulos; Anton Moritz; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

7.  Infective endocarditis: clinical features in young and elderly patients.

Authors:  M S Terpenning; B P Buggy; C A Kauffman
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

8.  Clinical and morphological characteristics in Streptococcus bovis endocarditis: a comparison with other causative microorganisms in 177 cases.

Authors:  I Kupferwasser; H Darius; A M Müller; S Mohr-Kahaly; T Westermeier; H Oelert; R Erbel; J Meyer
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

Review 9.  What happened to the streptococci: overview of taxonomic and nomenclature changes.

Authors:  Richard Facklam
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor.

Authors:  M F Tripodi; L E Adinolfi; E Ragone; E Durante Mangoni; R Fortunato; D Iarussi; G Ruggiero; R Utili
Journal:  Clin Infect Dis       Date:  2004-04-28       Impact factor: 9.079

View more
  1 in total

1.  Streptococcus bovis endocarditis: analysis of cases between 2005 and 2014.

Authors:  Renato Mello; Marisa da Silva Santos; Wilma Golebiosvki; Clara Weksler; Cristiane Lamas
Journal:  Braz J Infect Dis       Date:  2015-01-27       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.